Keyword: Fidelity Biosciences
BioNTech earmarked its considerable series A round for the development of its clinical pipeline, which includes mRNA-based cancer vaccines, a CAR-T treatment and a T cell receptor therapy for various solid tumors.
The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year.
GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.
Investors plowed $116 million in a Series B round into Unity Biotechnology, which is focusing its early work on halting atherosclerotic disease.
Specialty pharma spinout Castle Creek Pharmaceuticals has raised its first institutional round of $48 million entirely from active biotech crossover investor Fidelity Management and Research Company.